Press release

Mabion Announces Agreement with Novavax for Large-Scale Vaccine Manufacturing Feasibility Assessment

Konstantynów Łódzki, Poland, March 3rd, 2021 – Mabion (Warsaw Stock Exchange (WSE): MAB), a Polish biotechnology company focused on biopharmaceutical development and production, today announced a framework agreement for the production of technical batches of antigen for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, as an initial step toward a potential manufacturing contract. Upon Mabion’s successful production of the technical batches, the parties may enter into a broader contract for the production of antigen for NVX-CoV2373 for commercial use, should it be approved by regulatory agencies. With this Agreement, Mabion may become the first Polish company engaged in the worldwide effort to supply sufficient quantities of COVID-19 vaccines to serve the global need.

“The framework agreement with Novavax is an important opportunity for Mabion to leverage our expertise and capabilities in this important effort to combat the ongoing global pandemic,” said Dr. Dirk Kreder, CEO, President of the Management Board of Mabion S.A. “Our team of experts as well as our infrastructure are in the starting block, ready to initiate the production optimization and scale-up of Novavax’ promising vaccine candidate. We look forward to a close cooperation with Novavax, which may pave the way for commercial scale production, provided that technology transfer and technical batch are successfully completed.”

Under the terms of the agreement, Mabion and Novavax will work together to transfer technology for the production of a technical batch of NVX-CoV2373, allowing for the assessment of manufacturing feasibility at a commercial scale. These initial steps for demonstration of feasibility will be conducted over the course of the first half of 2021. Upon successful completion, Mabion’s manufacturing facility could become a part of the supply chain for commercial production of Novavax' adjuvanted protein-based vaccine candidate.

Mabion will utilize its expertise in protein engineering, analytics and drug manufacturing at its state-of-the-art facility, recently re-certified for Good Manufacturing Practice (GMP) production, to optimize the production process and produce a full-scale technical batch. This batch, as well as other elements stipulated in the first stage of the contract, will be funded by non-refundable remuneration from Novavax. The Agreement specifies the details of the first work order, while the scope of further potential orders will be covered in potential subsequent contracts. Based on the signed Agreement, it is too premature to define the future scale of the cooperation with Novavax, or the eventual scope of work.

About Mabion
Mabion is a Polish biotechnology company whose primary objective is to develop, manufacture and market biopharmaceutical medicines. The Company's lead project is MabionCD20, for which Mabion is pursuing registration in the EU through its partnership with Viatris (formerly Mylan) and subsequently in the US. Mabion is listed on the WSE main market since 2013 and is included in the mWIG40 index. For more information: www.mabion.eu.

Media contacts for Mabion:
Jakub Radzewicz
tel.: +48 601 155 582
e-mail: j.radzewicz@pov.pl